



To Whom It May Concern:

Basel, 25 August 2022

Polivy 30 mg powder for concentrate for solution for infusion
Polivy 140 mg powder for concentrate for solution for infusion

The nominal amount (without overfill) per 1 vial Polivy 30 mg is:

Ingredients	Quantity/Vial
Polatuzumab vedotin	30 mg
Succinic acid	1.77 mg
Sodium hydroxide (for pH-adjustment)	0.82 mg
Sucrose	62 mg
Polysorbate 20 (E 432)	1.8 mg
SWFI (sterile water for injection)	1.8 mL

The nominal amount (without overfill) per 1 vial Polivy 140 mg is:

Ingredients	Quantity/Vial
Polatuzumab vedotin	140 mg
Succinic acid	8.27 mg
Sodium hydroxide (for pH-adjustment)	3.80 mg
Sucrose	288 mg
Polysorbate 20 (E 432)	8.4 mg
SWFI (sterile water for injection)	7.2 mL

The density of Polivy 30 mg and 140 mg vial (lyophilized powder for concentrate for solution for infusion) reconstituted with SWFI is 1.02 g/mL at room temperature.

Roche Registration GmbH

Emil-Barell-Straße 1
D-79639 Grenzach-Wyhlen
Germany
Telefon +49 7624 14 2892
Telefax +49 7624 1015

Sitz der Gesellschaft:
Grenzach-Wyhlen
Registergericht:
Freiburg HRB 717155

Geschäftsführung:
Dr. Julia Wagle
USt-IdNr.: DE314809599

On behalf of Roche Registration GmbH,

ppa.

ppa.



Christelle Laroche
Pharma Technical Regulatory



Dr. Markus Boutellier
Pharma Technical Regulatory

Roche Registration GmbH

Emil-Barell-Straße 1
D-79639 Grenzach-Wyhlen
Germany
Telefon +49 7624 14 2892
Telefax +49 7624 1015

Sitz der Gesellschaft:
Grenzach-Wyhlen
Registergericht:
Freiburg HRB 717155

Geschäftsführung:
Dr. Julia Wagle
USt-IdNr.: DE314809599